ANNX: ARCHER II's month-15 vision-loss readout is expected in Q4 2026

What happened

ARCHER phase II showed dose-dependent vision protection, including a 73% reduction versus sham in the risk of confirmed 15-letter vision loss. ARCHER II enrolled 659 patients, and its month-15 results are expected in Q4 2026, with two sub-study analyses expected in Q1 2027.

Confirmed

Global impact / market context

The ARCHER II results could clarify whether the earlier vision-protection signal holds in a larger patient group. If the findings support that signal, they could influence expectations for Annexon’s research program and potential future commercial opportunity; disappointing results could weaken those expectations.

Analyst inference

The article provides trial timing and earlier phase II results, but no current share-price reaction, financial forecast, or regulatory decision. As a result, the clearest potential company-level driver is whether the upcoming data confirm the reported vision protection, not any established revenue change today.

Analyst inference

What to watch

1. Watch for ARCHER II’s month-15 results in Q4 2026, which will report outcomes from the 659 enrolled patients and test the earlier protection signal. Confirmed
2. The two sub-study analyses are expected in Q1 2027; their findings could add detail about how consistently vision outcomes differ from the sham group. Confirmed
3. Compare the full results with the reported 73% reduction in confirmed 15-letter loss risk; a weaker result could reduce confidence in the program’s prospects. Analyst inference

Evidence

• Original source link unavailable